Introduction
Atherosclerosis has become one of the major causes of death worldwide because of its severe complications, such as acute myocardial infarction and stroke (1) . Vascular endothelial cell (EC) activation is an initial step of atherosclerosis. ECs are responsive to various chemical and mechanical stimuli, including tumor necrosis factor α, lipopolysaccharide, and shear stress. EC activation triggers inflammatory responses to increase the expression of intercellular adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1), and the subsequent local recruitment of immune cells (2) . As the interface between circulating blood and the vessel wall, ECs are constantly exposed to mechanical forces generated by blood flow. Atherosclerosis preferentially develops at branches and curvatures in the arterial tree where flow is disturbed. In contrast, the flow in straight parts of the arteries generates laminar shear stress (LSS), which is atheroprotective (3) .
The Hippo pathway plays an evolutionarily conserved fundamental role in controlling organ size (4) . The core components of the mammalian Hippo pathway contain kinase cascade of mammalian Ste20-like kinases 1/2 (Mst1/2) and large tumor suppressor 1/2 (Lats1/2). Mst1/2, in complex with a regulatory protein salvador (Sav1), phosphorylates and activates Lats1/2, which also forms a complex with a regulatory protein Mps-one-binding (Mob1) (5) . The transcription coactivator Yes-associated protein (YAP) is a major downstream effector of the Hippo pathway (6) . When the Hippo signaling pathway is inactivated, YAP and its paralog TAZ translocate into the nucleus and activate gene transcription by binding to the TEAD family and other transcription factors (4) . The subcellular localization of YAP, which is important for its transcriptional activity, is regulated by its phosphorylation status. Phosphorylation at S 127 of YAP leads to its direct binding to 14-3-3 and retention in cytoplasm (4, 7) . Phosphorylation of YAP S 397 (S 381 ) by Lats1/2 promotes YAP ubiquitination-dependent degradation and reduces its nuclear localization (8) . In addition, phosphorylation of YAP at Y 357 increases its stability and in turn upregulates its activity (9) . Recently, YAP was identified to be crucial in ECs in different biological processes, including angiogenesis (10) and atherosclerosis (11, 12) . Moreover, the suppression of YAP in response to LSS plays an important role in maintaining vessel homeostasis in ECs (11, 12) . However, the regulation of YAP by OSS and the underlying mechanism is largely unknown.
Integrins, a diverse family of cell-surface heterodimeric proteins that facilitate cell-extracellular matrix (ECM) adhesion (13) , are associated with endothelial activation (14) (15) (16) . We and other groups identified integrin α5β1 as a membrane mechanical sensor responsive to OSS and with a proinflammatory and atheroprone role in ECs (17) (18) (19) . Additionally, fibronectin, as an endogenous ligand that activates integrin α5β1 (20) , can amplify the effect of oscillatory flow on EC activation (19) . In contrast, an integrin α5 inhibitor peptide, ATN161, retards the development of atherosclerosis (17) . However, the signal transduction underlying integrin activation remains unknown.
Nonreceptor protein tyrosine kinases (NRTKs), which transfer phosphate groups to tyrosine residues on protein substrates in the cytoplasm, are important components of signaling pathways Local flow patterns determine the uneven distribution of atherosclerotic lesions. This research aims to elucidate the mechanism of regulation of nuclear translocation of Yes-associated protein (YAP) under oscillatory shear stress (OSS) in the atheroprone phenotype of endothelial cells (ECs). We report here that OSS led to tyrosine phosphorylation and strong, continuous nuclear translocation of YAP in ECs that is dependent on integrin α5β1 activation. YAP overexpression in ECs blunted the anti-atheroprone effect of an integrin α5β1-blocking peptide (ATN161) in Apoe -/-mice. Activation of integrin α5β1 induced tyrosine, but not serine, phosphorylation of YAP in ECs. Blockage of integrin α5β1 with ATN161 abolished the phosphorylation of YAP at Y 357 induced by OSS. Mechanistic studies showed that c-Abl inhibitor attenuated the integrin α5β1-induced YAP tyrosine phosphorylation. Furthermore, the phosphorylation of c-Abl and YAP Y357 was significantly increased in ECs in atherosclerotic vessels of mice and in human plaques versus normal vessels. Finally, bosutinib, a tyrosine kinase inhibitor, markedly reduced the level of YAP Y357 and the development of atherosclerosis in Apoe -/-mice. The c-Abl/YAP Y357 pathway serves as a mechanism for the activation of integrin α5β1 and the atherogenic phenotype of ECs in response to OSS, and provides a potential therapeutic strategy for atherogenesis. to mediate OSS-induced EC activation (17) , and fibronectin is a major endogenous ligand of integrin α5β1 (22), we detected YAP nuclear translocation in ECs seeded on fibronectin-coated plates. As shown in Figure 1 , E and F, both integrin α5β1 activation and YAP nuclear translocation were induced by fibronectin, as evidenced by immunofluorescent staining. Western blot analysis also indicated that YAP nuclear translocation was increased with fibronectin treatment (Figure 1 , G and H).
To further test whether the regulation of YAP in response to OSS depends on integrin α5β1, we used ATN161, an integrin α5β1-blocking peptide, in OSS-treated ECs. Pretreatment with ATN161 did not alter the YAP subcellular localization in HUVECs under static conditions, but completely blocked the OSS-induced YAP nuclear translocation ( Figure 1, I and J). Moreover, in vivo evidence was obtained by examining the subcellular distribution of YAP in aortas of WT and Itga5 heterozygous knockout (α5 +/-) mice. As shown in Figure 1K , YAP exhibited nuclear localization in the inner curvature of the aortic arch (AA) but not the outer curvature of the AA or the thoracic aorta (TA) of WT mice. The flow pattern-dependent difference of YAP cellular distribution was abated in α5 +/-mice ( Figure 1K ). Thus, integrin α5β1 is essential in flowinduced YAP subcellular localization in vivo.
EC-specific YAP overexpression blunts the atheroprotective effect of integrin α5β1 blockage. Next, we asked whether YAP overexpression could abolish the beneficial effects of integrin α5β1 inhibition in vivo. To answer this question, we crossbred loxpstop-loxp YAP-transgenic mice with Tie2-Cre mice to generate Tie2-Cre Figure 2F and Supplemental Figure 1E ). These results indicate that YAP is an important downstream effector of integrin α5β1 in EC activation.
OSS induced phosphorylation of YAP at Tyr357 through integrin α5β1. Because the cellular localization of YAP was regulated by its protein phosphorylation modification, we determined the levels of YAP phosphorylation at Ser127 (4), Ser397 (8) , and Tyr357 (9) under OSS. OSS significantly increased the level of p-YAP Y357 , while decreasing that of p-YAP S127 without altering p-YAP S397 (Figure 3, A and B) . Simultaneously, the OSS activation of integrin α5β1 showed a similar time dependency as the p-YAP Y357 ( Figure 3, A and  B) . Fibronectin, as an agonist of integrin α5β1, dose-dependently upregulated the protein levels of both active-integrin α5β1 and (21) . NRTKs are divided into 9 main families according to their structures. Several kinases from different families, including focal adhesion kinase (FAK) and c-Src, mediate the signal transduction of integrins (22) . c-Abl has been shown to be colocalized with integrin α5 and activated in cells subjected to fibronectin treatment (23) or fluid shear stress (24) . Furthermore, with the emerging importance of NRTKs in neurodegenerative diseases, chronic myeloid leukemia, and carcinogenesis, tyrosine kinase inhibitors are being used in the clinic (21) . Although a spleen tyrosine kinase inhibitor, fostamatinib, has been found to attenuate atherogenesis in mice (25) , there is a paucity of information on the NRTKs as a potential target for treating atherosclerosis.
In this study, we investigated the regulation of YAP by OSS and the underlying mechanism in ECs. Our study provides both in vivo and in vitro evidence that activation of integrin α5β1 and its downstream kinase c-Abl mediates the OSS-induced YAP nuclear translocation via phosphorylating YAP at Y
357
. In addition, we have demonstrated that inhibition of c-Abl blunts the OSS-induced EC activation and the development of early-stage atherosclerosis.
Results
OSS increased YAP nuclear translocation via integrin α5β1. YAP, as a novel mechanosensor (26) , has been reported to promote EC activation in response to blood flow (12) . To investigate the effects of OSS on the pattern of YAP nuclear localization, human umbilical vein ECs (HUVECs) were subjected to OSS (0.5 ± 4 dyn/cm 2 , 1 Hz) for different durations. YAP showed significant nuclear localization beginning from 4 hours and sustained until 12 hours, as compared with static treatment ( tion of the fibronectin-induced p-YAP Y357 protein by 88% ( Figure  5B ). Consistent with these findings, immunofluorescence staining of YAP indicates that its fibronectin-induced nuclear localization was blocked by Src/c-Abl inhibitors ( Figure 5C and Supplemental Figure 2C ). In addition, nilotinib or bosutinib treatment did not affect the proliferation or apoptosis of ECs (Supplemental Figure 2, D-K) . Moreover, bosutinib treatment or siRNA-mediated knockdown of ABL1 decreased OSS-induced upregulation of p-YAP Y357 and VCAM-1 at protein level (Figure 5, D-G Figure 6, A and B) . Furthermore, the protein levels of p-c-Abl Y412 , p-YAP
Y357
, and the EC activation marker VCAM-1 were significantly increased in the AA intima tissue lysates than those of TA intima ( Figure 6 , C and D). Consistent with these results in mice, the expression of both p-c-Abl Y412 and p-YAP Y357 in ECs of human coronary arteries was high in plaques but not in normal vessels ( Figure 6 , E and F). Taken together, these findings indicate a predominant role of c-Abl in regulating YAP phosphorylation at Tyr357 to contribute to the development of flow-dependent atherosclerosis.
Bosutinib retarded both diet-induced and partial ligationinduced atherosclerosis in Apoe
-/-mice. In light of our finding that tyrosine kinase-mediated YAP phosphorylation might contribute to an atheroprone phenotype in ECs, bosutinib was injected into Apoe -/-mice that were fed a WTD for 4 or 12 weeks. Bosutinib significantly reduced the lesion area in aortas ( Figure 7A and Supplemental Figure 3A ). Oil Red O staining of whole aortas indicated that the reduction mainly occurred in the AA, where the lesion area was greatly decreased ( Figure 3N) . Next, we used Apoe -/-mice with partial ligation to further test the effect of bosutinib. Consistent with the diet-induced model, bosutinib significantly reduced the development of atherosclerosis ( Figure 7F ). En face immunofluorescence staining of ligated carotid arteries showed that the levels of EC inflammatory markers VCAM-1 and ICAM-1 were abolished by bosutinib administration (Figure 7, G and H) . These results indicate the atheroprotective effect of bosutinib on both early and advanced atherosclerosis.
Discussion
YAP has been identified as a mechanosensor of hemodynamic stress that contributes to EC activation in early-stage atherosclerosis (11, 12) . However, the transduction signaling pathway linking shear stress and YAP is still unknown. Here, we found that under OSS, YAP nuclear translocation was partly mediated by Src/c-Abl pathway participates in integrin α5β1-mediated YAP phosphorylation at Tyr357. We next explored which tyrosine kinase was involved in OSS-induced YAPY357 phosphorylation in ECs. Because FAK was reported to mediate fibronectin-induced integrin α5β1 activation in smooth muscle cells (27) , we first treated ECs with the FAK inhibitor PF-573228 (28) with or without fibronectin. PF-573228, which blocked fibronectin-mediated FAK phosphorylation at Tyr397, had no effect on p-YAP Y357 or YAP localization (Supplemental Figure 2, A and C) . Next, we treated ECs with the Src family inhibitor (SU6656) and c-Abl inhibitor (nilotinib). SU6656 decreased p-YAP Y357 by 19%, and nilotinib almost abolished the fibronectin-induced phosphorylation of YAP Y357 (Supplemental Figure 2B and Figure 5A ). The dual inhibition of the c-Abl and Src families by the use of bosutinib led to the reduc- a third-generation tyrosine kinase inhibitor of the Src/Abl pathway approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia that is resistant and/or intolerant to prior therapy, and it has a more favorable hematologic toxicity profile than other tyrosine kinase inhibitors (40) . Our results with animal models showed that bosutinib significantly reduced the lesion area in both diet-and ligation-induced atherosclerosis. Of note, bosutinib almost completely inhibited lesion formation in the AA but not TA in Apoe -/-mice; this strongly indicates that bosutinib attenuated the OSS-induced atheroprone effect. Hence, bosutinib may be a potential therapeutical agent for atherosclerotic diseases.
In conclusion, we found that the phosphorylation of YAP at Y357 and the consequent YAP activation in ECs are highly relevant in mouse and human atherosclerosis. OSS-or fibronectinmediated activation of integrin α5β1 and c-Abl serves as an important upstream signal to facilitate the phosphorylation of YAP at Y357 ( Figure 7I ). Our findings reveal a novel YAP activation mechanism and provide evidence that the integrin α5β1/c-Abl/YAP pathway is a potential therapeutic target for early-stage atherosclerosis.
Methods

Antibodies and reagents. Antibodies against p-YAP
(ab150361), activated integrin α5 (ab72663), vWF (ab6994, ab11713), and CD31 (ab24590, ab28364) were from Abcam; t-YAP (catalog 14074), p-YAP S127 (catalog 4911), p-YAP S397 (catalog 13619), VCAM-1 (catalog 39036 for IF), Ki67 (catalog 11882) and dylight 594 phalloidin (catalog 12877) were from Cell Signaling Technology; and ICAM-1 (sc-7891), SMA (sc-53142), Mac3 (sc-20004), and VCAM-1 (sc-8304) (for Western blot analysis) were from Santa Cruz Biotechnology. Activated integrin α5 for IF (MABT201) was from Merck. The in situ cell death detection kit, anti-rabbit and anti-mouse secondary antibodies, and fibronectin were from Sigma-Aldrich. Imatinib, nilotinib, and bosutinib were from Selleckchem. The integrin α5 inhibitor ATN161 (Ac-PHSCN-NH2) and scramble peptide (Ac-HSPNC-NH2) were synthesized with 98% peptide purity by ChinaPeptides.
Cell culture and shear stress experiments. Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as described (17, 41) . For flow experiments, confluent monolayers of HUVECs were seeded on glass slides, and a parallel plate flow system was used to impose oscillatory flow (0.5 ± 4 dyn/cm 2 ). THP-1 cells (ATCC, catalog TIB-202) were cultured with 1640 medium supplemented with 10% fetal bovine serum. The flow system was enclosed in a chamber held at 37°C and ventilated with 95% humidified air plus 5% CO 2 .
YAP recombinant adenovirus construction. Adenovirus expressing green fluorescent protein (Ad-GFP) and Ad-Flag-tagged human YAP (NM_001282101, Ad-YAP) were from GeneChem, as previously reported (10) . Ad-YAP Y357F was constructed using site-directed mutagenesis (GeneChem). HUVECs were infected with adenovirus at a multiplicity of infection (MOI) of 10, and no detectable cellular toxicity was observed. Western blot analysis. Cells or tissues were homogenized in cold RIPA lysis buffer supplemented with complete protease inhibitor cocktail and phosSTOP phosphatase inhibitor (Roche). Protein was resolved by SDS-PAGE and transferred to PVDF membrane (BioRad). Target protein was detected by using a specific primary antibody active integrin α5β1, which facilitates the activation of c-Abl and subsequent phosphorylation of YAP at Y 357 in vivo and in vitro. As a ligand of integrin α5β1, fibronectin also increased the phosphorylation of YAP at Y 357 via c-Abl. Use of a c-Abl inhibitor, bosutinib, greatly attenuated the development of both surgical partial ligation and dietary hypercholesterolemia-induced atherosclerosis in Apoe -/-mice. Atherosclerotic plaques occur in a nonrandom manner and tend to develop in the vasculature locations with low shear stress and OSS. In addition, the deposited ECM also contributes to the preferential distribution of the atherosclerotic lesions, which is regulated by different flow patterns (29) . For instance, the endothelium in atheroprotective regions resides on an ECM composed primarily of collagen IV and laminin (30) , whereas fibronectin is preferentially deposited in atheroprone regions (31) . Moreover, flow-induced tissue remodeling is highly dependent on ECM in atherosclerosis (32) . pUR4, a fibronectin polymerization inhibitor, reduced the deposition of fibronectin in carotid arteries and significantly blocked flow-mediated accumulation of inflammatory cells and vascular remodeling (32) . Besides the coupling of the external domain of integrins with the ECM to transduce signals into the cell, the conformational activation of integrin in responsive to ECMs is also induced by mechanical stimulation (33) .
In this study, we found that the activation of integrin α5β1 in ECs involved specifically the phosphorylation of YAP . These findings suggest that the activation of EC integrin α5β1 in response to atheroprone stimulations by both ECM fibronectin and OSS is dependent on YAP
Y357
. Importantly, we demonstrated the relevance of YAP Y357 to the atheroprone regions in 2 rodent atherosclerosis models and human plaques. Because of the apparent redundancy of the integrins responsive to these stimuli (34) , further experiments are needed to investigate the selective activation of integrins and their distinct downstream signaling pathways.
Tyrosine kinase is required to link the phosphorylation of YAP Y357 with the activation of integrin α5β1. Because of the structural diversity and varied catalytic domains of tyrosine kinases, the substrates of the tyrosine kinase family are distinguishable (35) . According to previous reports, peptides with the motif YXXP are considered better substrates for c-Abl than other tyrosine kinases, and this is similar to the sequence surrounding Y357 (36) . However, SU6656, a selective inhibitor for Src and other members of the Src family including Fyn and Yes (37) , also partially blocked the fibronectin-induced YAP Y357 phosphorylation. This might be the result of the crosstalk between the c-Abl and Src families. c-Abl kinase activity could be upregulated by members of the Src family, and c-Abl can be directly phosphorylated by Fyn kinase (38) . c-Abl also acts as a downstream effector of c-Src for growth factorinduced DNA synthesis (39) . It is to be noted that c-Abl inhibitor (nilotinib) blocked integrin α5β1-induced YAP Y357 phosphorylation more markedly than did the Src inhibitor.
Given the interaction between these 2 pathways (37), we next used a dual Src/Abl kinase inhibitor and found that bosutinib profoundly reduced YAP Y357 phosphorylation. Moreover, OSSinduced YAP activation was attenuated by bosutinib. Bosutinib is Quantification of lipid levels. Blood samples were collected by tail bleeding into heparin-coated tubes. Plasma was separated by centrifugation. Total plasma cholesterol (CHO), triglycerides (TGs), low density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were measured using kits from BioSino Bio-Technology and Science.
Human samples and staining. Human coronary arteries were obtained as we previously reported (42) . Briefly, coronary arteries with or without atherosclerotic plaque were collected from the Verification Centre of Forensic Medicine affiliated with Shantou University. Immunofluorescence and HE staining were performed.
Statistics. Sample sizes were designed with adequate power according to the literature and our previous studies. No sample outliers were excluded. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. The variance between the groups that were being statistically compared was similar. Data are mean ± SEM. Statistical analysis involved use of GraphPad Prism 6 by 2-tailed, unpaired Student's t test, and 1-way ANOVA or 2-way ANOVA with Bonferroni multiple comparison post hoc test, as appropriate. In all experiments, P less than 0.05 was considered statistically significant.
Study approval. Studies using autopsy tissue were approved by the Ethics Committee of Tianjin Medical University. Family members of subjects provided written informed consent for autopsy. The investigation conformed to the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). All animal protocols were reviewed and approved by the Animal Care and Use Committee at Tianjin Medical University.
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